Tritiated platelet imipramine binding and treatment response in depressed outpatients

Arthur M. Freeman, Srdjan M I Stankovic, Ronald J. Bradley, Gho‐Zhu ‐Z Zhang, J. Wesley Libb, Charles Nemeroff

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Mirtazapine was administered to 35 outpatients who participated in a clinical drug trial. This new antidepressant is structurally and pharmacologically similar to mianserin. Blood was obtained for the measurement of platelet [3H]‐imipramine binding before and after drug treatment. The treatment outcome groups were divided into three groups: those with the most rapid response, nonresponders, and slow responders. The rapid response group had the highest mean pretreatment binding and was presumably the placebo responders. Patients were classified as rapid responders if they showed a 50% reduction in Hamilton Depression Rating Scale (HDRS) after 2 weeks of treatment. Slow responders had the lowest mean Bmax and were felt to be the medication responders. Differences between the three groups were statistically significant. These differences in pretreatment Bmax values were sustained after controlling for the effects of age, protein concentration, maximum drug dosage, and HDRS scores. Only the slow treatment responder group, the presumed medication responders, showed significant change from pretreatment to post treatment Bmax. This study represents one of the first, which uses pretreatment density of platelet imipramine binding sites to predict antidepressant response. Moreover, drug treatment and concomitant recovery was associated with increased [3H]‐imipramine binding density. Depression 1:20–23 (1993). © 1993 Wiley‐Liss, Inc.

Original languageEnglish (US)
Pages (from-to)20-23
Number of pages4
JournalDepression
Volume1
Issue number1
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Imipramine
Outpatients
Blood Platelets
Pharmaceutical Preparations
Antidepressive Agents
Mianserin
Therapeutics
Binding Sites
Placebos
Clinical Trials
Proteins

Keywords

  • HRDS
  • Mirtazapine
  • [H]‐imipramine

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Freeman, A. M., Stankovic, S. M. I., Bradley, R. J., Zhang, GZ. Z., Libb, J. W., & Nemeroff, C. (1993). Tritiated platelet imipramine binding and treatment response in depressed outpatients. Depression, 1(1), 20-23. https://doi.org/10.1002/depr.3050010105

Tritiated platelet imipramine binding and treatment response in depressed outpatients. / Freeman, Arthur M.; Stankovic, Srdjan M I; Bradley, Ronald J.; Zhang, Gho‐Zhu ‐Z; Libb, J. Wesley; Nemeroff, Charles.

In: Depression, Vol. 1, No. 1, 1993, p. 20-23.

Research output: Contribution to journalArticle

Freeman, AM, Stankovic, SMI, Bradley, RJ, Zhang, GZZ, Libb, JW & Nemeroff, C 1993, 'Tritiated platelet imipramine binding and treatment response in depressed outpatients', Depression, vol. 1, no. 1, pp. 20-23. https://doi.org/10.1002/depr.3050010105
Freeman, Arthur M. ; Stankovic, Srdjan M I ; Bradley, Ronald J. ; Zhang, Gho‐Zhu ‐Z ; Libb, J. Wesley ; Nemeroff, Charles. / Tritiated platelet imipramine binding and treatment response in depressed outpatients. In: Depression. 1993 ; Vol. 1, No. 1. pp. 20-23.
@article{d1686b90b48c4f33a689c6c8cb9405f7,
title = "Tritiated platelet imipramine binding and treatment response in depressed outpatients",
abstract = "Mirtazapine was administered to 35 outpatients who participated in a clinical drug trial. This new antidepressant is structurally and pharmacologically similar to mianserin. Blood was obtained for the measurement of platelet [3H]‐imipramine binding before and after drug treatment. The treatment outcome groups were divided into three groups: those with the most rapid response, nonresponders, and slow responders. The rapid response group had the highest mean pretreatment binding and was presumably the placebo responders. Patients were classified as rapid responders if they showed a 50{\%} reduction in Hamilton Depression Rating Scale (HDRS) after 2 weeks of treatment. Slow responders had the lowest mean Bmax and were felt to be the medication responders. Differences between the three groups were statistically significant. These differences in pretreatment Bmax values were sustained after controlling for the effects of age, protein concentration, maximum drug dosage, and HDRS scores. Only the slow treatment responder group, the presumed medication responders, showed significant change from pretreatment to post treatment Bmax. This study represents one of the first, which uses pretreatment density of platelet imipramine binding sites to predict antidepressant response. Moreover, drug treatment and concomitant recovery was associated with increased [3H]‐imipramine binding density. Depression 1:20–23 (1993). {\circledC} 1993 Wiley‐Liss, Inc.",
keywords = "HRDS, Mirtazapine, [H]‐imipramine",
author = "Freeman, {Arthur M.} and Stankovic, {Srdjan M I} and Bradley, {Ronald J.} and Zhang, {Gho‐Zhu ‐Z} and Libb, {J. Wesley} and Charles Nemeroff",
year = "1993",
doi = "10.1002/depr.3050010105",
language = "English (US)",
volume = "1",
pages = "20--23",
journal = "Depression",
issn = "1062-6417",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Tritiated platelet imipramine binding and treatment response in depressed outpatients

AU - Freeman, Arthur M.

AU - Stankovic, Srdjan M I

AU - Bradley, Ronald J.

AU - Zhang, Gho‐Zhu ‐Z

AU - Libb, J. Wesley

AU - Nemeroff, Charles

PY - 1993

Y1 - 1993

N2 - Mirtazapine was administered to 35 outpatients who participated in a clinical drug trial. This new antidepressant is structurally and pharmacologically similar to mianserin. Blood was obtained for the measurement of platelet [3H]‐imipramine binding before and after drug treatment. The treatment outcome groups were divided into three groups: those with the most rapid response, nonresponders, and slow responders. The rapid response group had the highest mean pretreatment binding and was presumably the placebo responders. Patients were classified as rapid responders if they showed a 50% reduction in Hamilton Depression Rating Scale (HDRS) after 2 weeks of treatment. Slow responders had the lowest mean Bmax and were felt to be the medication responders. Differences between the three groups were statistically significant. These differences in pretreatment Bmax values were sustained after controlling for the effects of age, protein concentration, maximum drug dosage, and HDRS scores. Only the slow treatment responder group, the presumed medication responders, showed significant change from pretreatment to post treatment Bmax. This study represents one of the first, which uses pretreatment density of platelet imipramine binding sites to predict antidepressant response. Moreover, drug treatment and concomitant recovery was associated with increased [3H]‐imipramine binding density. Depression 1:20–23 (1993). © 1993 Wiley‐Liss, Inc.

AB - Mirtazapine was administered to 35 outpatients who participated in a clinical drug trial. This new antidepressant is structurally and pharmacologically similar to mianserin. Blood was obtained for the measurement of platelet [3H]‐imipramine binding before and after drug treatment. The treatment outcome groups were divided into three groups: those with the most rapid response, nonresponders, and slow responders. The rapid response group had the highest mean pretreatment binding and was presumably the placebo responders. Patients were classified as rapid responders if they showed a 50% reduction in Hamilton Depression Rating Scale (HDRS) after 2 weeks of treatment. Slow responders had the lowest mean Bmax and were felt to be the medication responders. Differences between the three groups were statistically significant. These differences in pretreatment Bmax values were sustained after controlling for the effects of age, protein concentration, maximum drug dosage, and HDRS scores. Only the slow treatment responder group, the presumed medication responders, showed significant change from pretreatment to post treatment Bmax. This study represents one of the first, which uses pretreatment density of platelet imipramine binding sites to predict antidepressant response. Moreover, drug treatment and concomitant recovery was associated with increased [3H]‐imipramine binding density. Depression 1:20–23 (1993). © 1993 Wiley‐Liss, Inc.

KW - HRDS

KW - Mirtazapine

KW - [H]‐imipramine

UR - http://www.scopus.com/inward/record.url?scp=85005231330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85005231330&partnerID=8YFLogxK

U2 - 10.1002/depr.3050010105

DO - 10.1002/depr.3050010105

M3 - Article

VL - 1

SP - 20

EP - 23

JO - Depression

JF - Depression

SN - 1062-6417

IS - 1

ER -